- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Real-world Multiple Myeloma Treatment: Insights and Challenges
Experts discuss findings from real-world studies comparing DRd with VRD, emphasizing the importance of individualized dosing and supportive care, and navigate challenges in incorporating real-world data.
EP: 1.Unmet Needs In Multiple Myeloma Management
EP: 2.Evolving Goals in Multiple Myeloma Treatment
EP: 3.Multiple Myeloma Induction Challenges and Future Options
EP: 4.Optimizing Multiple Myeloma Treatment: Quadruplet Therapy
EP: 5.Real-World Insights: Multiple Myeloma Treatment Challenges
EP: 6.Navigating the Multiple Myeloma Treatment Landscape
EP: 7.Real-world Multiple Myeloma Treatment: Insights and Challenges
EP: 8.The Future of Multiple Myeloma Treatment
EP: 9.ASH 2023: Multiple Myeloma's Shifting Landscape: Trials and Clinical Perspectives
EP: 10.Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs
This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.
Davies discusses real-world studies(RWS) comparing DRd (daratumumab) to other regimens. One study compared DRd from the MAIA trial with Flatiron Health database data, demonstrating a lower risk of progression for patients receiving DRd. Another retrospective study compared patients receiving DRd patients with those receiving VRd (bortezomib, lenalidomide, dexamethasone), reinforcing the potential usefulness of anti-CD38 in the upfront setting. Krishnan highlights challenges in collecting dosing data in RWS, emphasizing the need to refer to original trials for guidance. The conversation underscores the value of real-world data in corroborating and adjusting treatment strategies based on the actual patient population.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
